Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213)-Reference-Cited by-同舟云学术

Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213)

Published:2018-01-02 Issue:5 Volume:65 Page:e26944
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Norris Robin E.¹^ORCID,Fox Elizabeth²,Reid Joel M.³,Ralya Andrew³,Liu Xiaowei W.⁴,Minard Charles⁵,Weigel Brenda J.⁶

Affiliation:

1. Division of Oncology, Cancer and Blood Diseases Institute; Cincinnati Children's Hospital Medical Center; Cincinnati Ohio

2. The Children's Hospital of Philadelphia; Philadelphia Pennsylvania

3. Mayo Clinic; Rochester Minnesota

4. Children's Oncology Group Operations Center; Monrovia California

5. Dan L. Duncan Institute for Clinical and Translational Research; Baylor College of Medicine; Houston Texas

6. University of Minnesota Medical Center/Masonic Center Minneapolis; Minneapolis Minnesota

Funder

National Cancer Institute

National Institutes of Health

Cookies for Kids’ Cancer Foundation

Children's Oncology Group (COG) Foundation

St. Baldrick's Foundation

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference19 articles.

1. Endosialin/TEM-1/CD248 regulates pericyte proliferation through PDGF receptor signaling;Tomkowicz;Cancer Biol. Ther,2010

2. Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells;Christian;Am J Pathol.,2008

3. Endosialin expression in metastatic melanoma tumor microenvironment vasculature: potential therapeutic implications.;Kiyohara;Cancer Microenviron.,2015

4. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin;Dolznig;Cancer Immun.,2005

5. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer;Rettig;Proc Natl Acad Sci USA.,1992

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD248 promotes insulin resistance by binding to the insulin receptor and dampening its insulin-induced autophosphorylation;eBioMedicine;2024-01

2. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches;Theranostics;2024

3. CD248 Regulates Inflammation and Encapsulation in Silicone-Related Capsule Formation;Plastic & Reconstructive Surgery;2023-03-28

4. CD248 induces a maladaptive unfolded protein response in diabetic kidney disease;Kidney International;2023-02

5. TEM1 up-regulates MMP-2 and promotes ECM remodeling for facilitating invasion and migration of uterine sarcoma;Discover Oncology;2023-01-13